Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
adenosine
immunotherapy
liver neoplasms
macrophages
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
accepted:
16
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
16
9
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we examined the expression of CD38, a molecule involved in the immunosuppressive adenosinergic pathway, on immune cells present in the tumor microenvironment. We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC. Clinically annotated samples from 49 patients with advanced HCC treated with ICB were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF) and multiplex cytokine analysis. IHC and mIHC/IF analyses revealed that higher intratumoral CD38 A high proportion of CD38
Identifiants
pubmed: 32847986
pii: jitc-2020-000987
doi: 10.1136/jitc-2020-000987
pmc: PMC7451957
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM112017
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: DT is in the advisory board in MSD for clinical trials, and as research support in BMS. FM received research support from Janssen Pharmaceuticals, Celgene, Tusk Therapeutics and Centrose, and served on advisory boards for Centrose, Tusk Therapeutics, Jenssen, Takeda and Sanofi. JJXL has research funding from Bayer and has participated in advisory boards for Ipsen and Bayer.
Références
Oncotarget. 2019 Jun 18;10(40):4018-4025
pubmed: 31258846
Oncogene. 2010 Sep 30;29(39):5346-58
pubmed: 20661219
Immunol Rev. 1998 Feb;161:79-93
pubmed: 9553766
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493
pubmed: 29662547
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
FEBS Lett. 2011 Jun 6;585(11):1514-20
pubmed: 21514298
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Carcinogenesis. 2012 Jan;33(1):209-19
pubmed: 22021908
J Clin Pathol. 2018 Feb;71(2):161-167
pubmed: 28735300
J Immunother Cancer. 2016 Aug 16;4:48
pubmed: 27532023
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Ann Clin Lab Sci. 2015 Fall;45(5):528-32
pubmed: 26586704
JAMA Oncol. 2017 Jul 1;3(7):974-978
pubmed: 28334399
Crit Rev Immunol. 2015;35(5):417-32
pubmed: 26853852
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Sci Transl Med. 2016 Feb 24;8(327):327ra26
pubmed: 26912905
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Physiol Rev. 2008 Jul;88(3):841-86
pubmed: 18626062
Virchows Arch. 2019 Dec;475(6):709-725
pubmed: 31407032
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
Ann Surg. 2017 Oct;266(4):693-701
pubmed: 28650354
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Br J Surg. 2006 May;93(5):600-6
pubmed: 16607679
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Res. 2014 Jul 15;74(14):3652-8
pubmed: 24986517
J Clin Pathol. 2012 Jun;65(6):496-502
pubmed: 22447914
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Front Immunol. 2018 Jul 10;9:1593
pubmed: 30042766
J Biol Chem. 2012 Apr 27;287(18):14502-14
pubmed: 22396532
Oncotarget. 2016 Sep 20;7(38):61378-61389
pubmed: 27542216
Diagn Pathol. 2018 Feb 9;13(1):12
pubmed: 29426340
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6
pubmed: 23964122
Front Immunol. 2019 Sep 04;10:2093
pubmed: 31552039
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Cell. 2014 Oct 23;159(3):691-6
pubmed: 25417115
J Thorac Oncol. 2016 Jan;11(1):62-71
pubmed: 26762740
Hum Pathol. 2014 May;45(5):1092-9
pubmed: 24746216
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Diagn Pathol. 2018 Dec;37:12-19
pubmed: 30218928
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
J Immunother Cancer. 2019 Nov 27;7(1):325
pubmed: 31775882
Breast Cancer Res Treat. 2019 Nov;178(2):295-305
pubmed: 31410680
Clin Cancer Res. 2017 Mar 15;23(6):1373-1378
pubmed: 28039261
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Clin Cancer Res. 2018 Jan 15;24(2):407-419
pubmed: 29074606
J Biol Chem. 2012 Sep 14;287(38):31633-40
pubmed: 22822066
Cancer Cell. 2019 Dec 9;36(6):582-596
pubmed: 31821783
J Immunol. 2016 May 1;196(9):3943-50
pubmed: 26994219
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Breast Cancer Res Treat. 2017 May;163(1):21-35
pubmed: 28233108
Front Immunol. 2016 Mar 29;7:109
pubmed: 27066002
Nature. 2015 Apr 2;520(7545):94-8
pubmed: 25600267
Pathology. 2018 Apr;50(3):333-341
pubmed: 29429740
Leukemia. 2002 Jan;16(1):30-5
pubmed: 11840260
Front Immunol. 2018 May 30;9:1209
pubmed: 29899747
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Nat Immunol. 2019 Sep;20(9):1231-1243
pubmed: 31358999
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Cells. 2019 Dec 20;9(1):
pubmed: 31861847
Clin Mol Hepatol. 2015 Jun;21(2):105-14
pubmed: 26157746
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Cancer Immunol Immunother. 2012 Jun;61(6):917-26
pubmed: 22116345
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724788
Nat Med. 2015 Sep;21(9):998-1009
pubmed: 26236991
Infect Immun. 2013 Nov;81(11):4091-9
pubmed: 23980105
Breast Cancer Res Treat. 2016 Apr;156(2):237-47
pubmed: 26960711
Genome Res. 2013 Sep;23(9):1422-33
pubmed: 23788652
Oncologist. 2017 Nov;22(11):1392-1399
pubmed: 28835513
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Gut. 2019 May;68(5):916-927
pubmed: 29970455
Nat Commun. 2018 Oct 22;9(1):4383
pubmed: 30348985
Sci Rep. 2020 Jan 20;10(1):643
pubmed: 31959763
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Oncologist. 2016 May;21(5):643-50
pubmed: 27026676
Cells. 2015 Sep 17;4(3):520-37
pubmed: 26393653
Cancer Immunol Res. 2020 Mar;8(3):334-344
pubmed: 31871122
Mol Cancer. 2017 Jun 7;16(1):99
pubmed: 28592285
Breast Cancer Res. 2016 Mar 22;18(1):35
pubmed: 27000374